Hypoxia favors chemoresistance in T-ALL through an HIF1?-mediated mTORC1 inhibition loop.

ABSTRACT: Resistance to chemotherapy, a major therapeutic challenge in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), can be driven by interactions between leukemic cells and the microenvironment that promote survival of leukemic cells. The bone marrow, an important leukemia niche, has low oxygen partial pressures that highly participate in the regulation of normal hematopoiesis. Here we show that hypoxia inhibits T-ALL cell growth by slowing down cell cycle progression, decreasing mitochondria activity, and increasing glycolysis, making them less sensitive to antileukemic drugs and preserving their ability to initiate leukemia after treatment. Activation of the mammalian target of rapamycin (mTOR) was diminished in hypoxic leukemic cells, and treatment of T-ALL with the mTOR inhibitor rapamycin in normoxia mimicked the hypoxia effects, namely decreased cell growth and increased quiescence and drug resistance. Knocking down (KD) hypoxia-induced factor 1? (HIF-1?), a key regulator of the cellular response to hypoxia, antagonized the effects observed in hypoxic T-ALL and restored chemosensitivity. HIF-1? KD also restored mTOR activation in low O2 concentrations, and inhibiting mTOR in HIF1? KD T-ALL protected leukemic cells from chemotherapy. Thus, hypoxic niches play a protective role of T-ALL during treatments. Inhibition of HIF-1? and activation of the mTORC1 pathway may help suppress the drug resistance of T-ALL in hypoxic niches.

SUBMITTER: Fahy L 

PROVIDER: S-EPMC7839374 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature